AstraZeneca and Mitsubishi Tanabe Pharma to collaborate on diabetic nephropathy
Anglo-Swedish drug major AstraZeneca (LSE: AZN) has entered into a three-year research collaboration on diabetic nephropathy with Japanese pharma company Mitsubishi Tanabe Pharma (TYO: 4508).
The companies are aiming to leverage their strengths and assets to encourage the progress of molecules into clinical development, from target selection to the delivery of small molecule candidate drugs. The research is to be carried out in parallel at Mitsubishi Tanabe’s facilities in Japan, and at AstraZeneca’s plant in Sweden. Neither company is required to make a financial commitment to the research, and both will contribute equal resources at their own cost.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze